Skip to main content
eScholarship
Open Access Publications from the University of California

Xenobiotic metabolizing gene variants and renal cell cancer: a multicenter study.

  • Author(s): Heck, Julia E
  • Moore, Lee E
  • Lee, Yuan-Chin A
  • McKay, James D
  • Hung, Rayjean J
  • Karami, Sara
  • Gaborieau, Valérie
  • Szeszenia-Dabrowska, Neonila
  • Zaridze, David G
  • Mukeriya, Anush
  • Mates, Dana
  • Foretova, Lenka
  • Janout, Vladimir
  • Kollárová, Helena
  • Bencko, Vladimir
  • Rothman, Nathaniel
  • Brennan, Paul
  • Chow, Wong-Ho
  • Boffetta, Paolo
  • et al.
Abstract

The countries of Central and Eastern Europe have among the highest worldwide rates of renal cell cancer (RCC). Few studies have examined whether genetic variation in xenobiotic metabolic pathway genes may modify risk for this cancer.The Central and Eastern Europe Renal Cell Cancer study was a hospital-based case-control study conducted between 1998 and 2003 across seven centers in Central and Eastern Europe. Detailed data were collected from 874 cases and 2053 controls on demographics, work history, and occupational exposure to chemical agents. Genes [cytochrome P-450 family, N-acetyltransferases,quinone oxidoreductase I (NQO1), microsomal epoxide hydrolase (mEH), catechol-O-methyltransferase (COMT), uridine diphosphate-glucuronosyltransferase (UGT)] were selected for the present analysis based on their putative role in xenobiotic metabolism. Haplotypes were calculated using fastPhase. Odds ratios and 95% confidence intervals were estimated by unconditional logistic regression adjusted for country of residence, age, sex, smoking, alcohol intake, obesity, and hypertension.We observed an increased risk of RCC with one SNP. After adjustment for multiple comparisons it did not remain significant. Neither NAT1 nor NAT2 slow acetylation was associated with disease.We observed no association between this pathway and renal cell cancer.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View